Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 1843-1849

  Park, Ki Ho ^a,b   Kim, Eun Sil ^a,b   Kim, Hee Seung ^a,b   Park, Su Jin ^a,b   Bang, Kyung Mi ^a,b   Park, Hyun Jung ^a,b   Park, So Youn ^a,b   Moon, Song Mi ^a,b   Chong, Yong Pil ^a,b   Kim, Sung Han ^a,b   Lee, Sang Oh ^a,b   Choi, Sang Ho ^a,b   Jeong, Jin Yong ^a,b   Kim, Mi Na ^a   Woo, Jun Hee ^a,b   Kim, Yang Soo ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

HVISA; Mortality; MRSA; Virulence factors

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; FUSIDIC ACID; GENTAMICIN; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL FEATURE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENOTYPE; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HETERORESISTANT VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION;

AGED; BACTEREMIA; COHORT STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE;

EID: 84864510176     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks131     Document Type: Article

References (33)

1. Cosgrove SE, Qi Y, Kaye KS et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26: 166-74.
2. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-22.
3. Fridkin SK, Hageman J, McDougal LK et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin Infect Dis 2003; 36: 429-39.
4. Maor Y, Hagin M, Belausov N et al. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis 2009; 199: 619-24.
5. Howden BP, Johnson PD, Ward PB et al. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2006; 50: 3039-47.
6. Liu C, Chambers HF. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob Agents Chemother 2003; 47: 3040-5.
7. Rybak MJ, Leonard SN, Rossi KL et al. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008; 46: 2950-4.
8. van Hal SJ, Jones M, Gosbell IB et al. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One 2011; 6: e21217.
9. Howden BP, Davies JK, Johnson PD et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycinintermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
10. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
11. Ariza J, Pujol M, Cabo J et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
12. Bae IG, Federspiel JJ, Miro JM et al. Heterogeneous vancomycinintermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis 2009; 200: 1355-66.
13. Charles PG, Ward PB, Johnson PD et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38: 448-51.
14. Fong RK, Low J, Koh TH et al. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore. Eur J Clin Microbiol Infect Dis 2009; 28: 983-7.
15. Lodise TP, McKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36: 1418-23.
16. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically- Eighth Edition: Approved Standard M7-A8. CLSI, Wayne, PA, USA, 2009.
17. Wootton M, Howe RA, Hillman R et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001; 47: 399-403.
18. Jarraud S, Mougel C, Thioulouse J et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 2002; 70: 631-41.
19. Diep BA, Carleton HA, Chang RF et al. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 2006; 193: 1495-503.
20. Peacock SJ, Moore CE, Justice A et al. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun 2002; 70: 4987-96.
21. Campbell SJ, Deshmukh HS, Nelson CL et al. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol 2008; 46: 678-84.
22. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 2155-61.
23. Enright MC, Day NP, Davies CE et al. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 2000; 38: 1008-15.
24. Fowler VG Jr, Nelson CL, McIntyre LM et al. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis 2007; 196: 738-47.
25. Musta AC, Riederer K, Shemes S et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009; 47: 1640-4.
26. Watanabe Y, Cui L, Katayama Y et al. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J Clin Microbiol 2011; 49: 2680-4.
27. Khatib R, Jose J, Musta A et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66: 1594-9.
28. Moise PA, Smyth DS, El-Fawal N et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008; 61: 85-90.
29. Moreillon P, Bizzini A, Giddey M et al. Vancomycin-intermediate Staphylococcus aureus selected during vancomycin therapy of experimental endocarditis are not detected by culture-based diagnostic procedures and persist after treatment arrest. J Antimicrob Chemother 2012; 67: 652-60.
30. Horne KC, Howden BP, Grabsch EA et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillinresistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother 2009; 53: 3447-52.
31. Kullar R, Davis SL, Levine DP et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52: 975-81.
32. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
33. Neoh HM, Hori S, Komatsu M et al. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann Clin Microbiol Antimicrob 2007; 6: 13.